` 002007 (Hualan Biological Engineering Inc) vs Shanghai Composite Comparison - Alpha Spread

002007
vs
S
Shanghai Composite

Over the past 12 months, Hualan Biological Engineering Inc has underperformed Shanghai Composite, delivering a return of -11% compared to the Shanghai Composite's +15% growth.

Stocks Performance
002007 vs Shanghai Composite

Loading
002007
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
002007 vs Shanghai Composite

Loading
002007
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
002007 vs Shanghai Composite

Loading
002007
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Hualan Biological Engineering Inc vs Peers

Shanghai Composite
002007
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Hualan Biological Engineering Inc
Glance View

Market Cap
27.9B CNY
Industry
Biotechnology

Hualan Biological Engineering Inc., nestled in the heart of China, operates at the crossroads of innovation and health, focusing primarily on the production of vaccines and blood products. The company is at the forefront of a critical industry, ensuring the creation of products that play a pivotal role in maintaining public health. With a dedicated pursuit of scientific excellence, Hualan develops vaccines that protect against contagious diseases and specializes in plasma-derived therapeutics that have become a backbone in treating a variety of conditions requiring immune support or clotting factors. This dual focus not only showcases their expertise but also broadens their commercial portfolio, tapping into markets where demand is continually rising. Revenue streams for Hualan Biological are primarily driven by their deep penetration into domestic markets, where there is a growing emphasis on healthcare innovation and quality assurance. The company capitalizes on its research and development capabilities, which have enabled it to secure a strong pipeline of products and stay ahead in a competitive landscape. By leveraging its robust distribution network and quality manufacturing processes, Hualan ensures that its products reach hospitals and health institutions rapidly. This strategic orchestration of science and logistics allows Hualan not only to generate substantial revenues but also to reinforce its reputation as a leader within China's biopharmaceutical sector, ensuring it remains a vital contributor to public health initiatives.

Intrinsic Value
19.38 CNY
Undervaluation 21%
Intrinsic Value
Price
Back to Top